Skip to content

clinical research of osteogenesis imperfecta

clinical research of osteogenesis imperfecta

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074207
Enrollment
Unknown
Registered
2023-08-01
Start date
2022-11-03
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteogenesis imperfecta

Interventions

Underage group (<18 years old) and adult group (= 18 years old):None

Sponsors

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: (1) Recurrent fragility fractures. (2) Presence of extra skeletal phenotypes such as blue sclera, dentin hypoplasia, and hearing loss. (3) The presence of COL1A1, COL1A2, IFITM5, SERPINF1, CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, PLOD2, SP7, BMP1, TMEM38B, WNT1, CREB3L1, SPARC, SEC24D, P4HB, PLS3, MBTPS2, FAM46A, MESD, KDELR2, CCDC134, NBAS mutations in any gene. (4) Voluntary participation in this study.

Exclusion criteria

Exclusion criteria: (1) Other causes of low bone mass disease, such as primary osteoporosis, other causes of secondary osteoporosis, hypophosphatasia, osteochondrosis, etc. (2) Poor compliance and inability to follow up regularly. (3) Unwillingness to participate in this study.

Design outcomes

Primary

MeasureTime frame
Lumbar bone mineral density;

Secondary

MeasureTime frame
Bone turnover markers;Total hip bone mineral density;

Countries

China

Contacts

Public ContactHao Zhang

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

zhanghaozcl@163.com+86 139 1848 2691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026